Our recent experiments show high levels of the inflammatory cytokine IL-17A in iSGS airway scar. IL-17A also appears to drive c...

Jun 16, 2018

556

 
Inflammatory signals (IL17A) drive airway cells to create fibrosis (ie scar).
Our recent experiments show high levels of the inflammatory cytokine IL-17A in iSGS airway scar. IL-17A also appears to drive cells within the airway lining to proliferate and create scar.  We hope this finding will translate into better new treatments for iSGS. This type of work is only possible with the support of enthusiastic patients. 

Kat, beverley, and 9 others like this.

3 comments

Join the conversation!Sign In

Dawn sullivanBacker

I’m giving back, the debit I just got from the study!

Jun 23, 20180

Alexander GelbardResearcher

Kat, you are exactly right the small blue circle is TGF-B (beta). There are FDA approved drugs that block IL-17A (cosentyx and Talz). While there are not trials currently open to test this in iSGS - NoAAC is working on getting this going - so stay tuned.

Jun 16, 20184

Kat MacBacker

I can't quite read the small blue graphic IL17A to TGF-8? to activation? Are there any studies currently to see if already approved drugs that suppress IL-17 could aid in the slowing of (or prevention of) ISgS scaring?

Jun 16, 20181

About This Project

NoAAC Longitudinal Registry of Treatment Outcomes in iSGS

North American Airway Collaborative

Idiopathic subglottic stenosis (iSGS) is a rare and life-threatening disease involving airway obstruction. Given its rarity, a number of options for treatment have been developed. The proposed study will continue and extend the PCORI-funded study in iSGS conducted by the North American Airway Collaborative (NoAAC) to collect objective long-term data on outcomes and side effects. This information is critical to help patients decide on the best treatment.